$599

STEP UP Wegovy HD Data; New Novo Obesity + T1DM Study; Fractyl Q1 ’26 Earnings and CTA Authorization of RJVA-001; Roche 2026 Diagnostics Day

A series of cardiometabolic-related news items has been observed from Novo Nordisk, Fractyl Health, and Roche. Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.
Already a member? Log in here